Key Takeaways
- Resilient quarter despite demand headwinds: Gross margin expanded 290 bps to 68.8% on benign input costs, even as delayed winter and weak rural demand pressured volumes.
- Winter portfolio dragged volumes: A delayed, low-intensity winter caused a ~9% decline in winter products, driving overall volume down 0.9% and masking growth in the non-seasonal pain portfolio.
- D2C brands nearing breakeven: Man Company turned EBITDA-positive on ~80% growth, while Brillare’s negative EBITDA margin halved to minus 20%, signaling the digital-first bet is scaling toward profitability.
- Kesh King decline called a one-off: Management framed the 13% drop as a single-quarter blip against a 5% four-year CAGR, pinning it on downtrading in premium hair oil and expecting a bounce-back.
- What to watch next quarter: Whether Kesh King and the winter portfolio recover as seasonality normalizes, the pace of rural demand revival, and if D2C margin improvement continues.
Demand & Volume Dynamics
- Rural stress persisted: Lower offtakes from mass consumers in the low-income segment continued, mirroring Q2 trends, though moderating inflation and government budget allocations provide a tentative positive signal.
- Winter’s double hit: A delayed onset and lower intensity of winter directly hurt the winter portfolio, which is large in Q3, dragging overall volumes down 0.9% and masking growth elsewhere.
- Seasonality dependency falling: New launches are largely non-seasonal, and the pain portfolio, at 26% of revenues, is non-seasonal, structurally reducing the business’s vulnerability to weather shocks over time.
- Post-COVID consumption shift: Consumer funds diverted to discretionary spends like travel and eating out post-pandemic, creating a blip in core healthcare products like immunity and Chyawanprash.
Mohan Goenka: "Yes if you see last four years, Kesh King oil is at a 5% growth CAGR. When you compare pre-COVID levels, so this is one-off, a decline of 13%. It's not that the oil is declining."
Brand & Segment Performance
| Segment / Brand | Trend | Commentary |
|---|---|---|
| Pain portfolio | ▲ Resilient | At 26% of revenues and non-seasonal, it provided stability while winter products declined. |
| Winter portfolio | ▼ Declined ~9% | Delayed, low-intensity winter hit BoroPlus Cream, Navratna Oil and Cool Talc; Chyawanprash dragged healthcare flat. |
| Kesh King | ▼ 13% decline | Premium hair oil facing downtrading stress; onion and other new ranges performing better. Management expects bounce-back to 6-8% growth once market revives. |
| 7 Oils | ▼ Impacted | Discretionary slowdown weighed on performance this quarter. |
| Healthcare | ▬ Flat | Brands grew 5-7% but Chyawanprash decline dragged the portfolio; new launches provide entry into large categories. |
| International | ▲ Robust | MENAP region drove performance despite currency depreciation, Bangladesh elections, and Red Sea disruptions. |
| D2C brands | ▲ Scaling fast | Man Company EBITDA turned positive on ~80% growth; Brillare losses narrowed from 40-45% to minus 20%. |
- Zanducare consumer base: Millennials aged 25-35 buying as caregivers for parents or older siblings, a cohort growing month-on-month and quarter-on-quarter.
- Market share dynamics: In OTC, Pancharishta defines its category; in medico, smaller players are making state-level forays but Emami competes with larger players due to higher-cost WHO GMP manufacturing; in D2C, Emami is better positioned than peers who entered in the last 2-3 years.
New Launches & Innovation
- Zandu Agni Balm: A stronger multipurpose balm launched to counter regional competition and gain share from the overall balm portfolio.
- Dantveer toothpaste: An Ayurvedic toothpaste launched on the D2C portal Zanducare, with management citing Zandu’s established Ayurveda credentials and a “winner formulation” as its right to win in a high-margin category.
- International launches: Pure glycerin oil under Creme21 and a conditioning shampoo range under 7 Oils in One launched in select international markets.
- Digital-first pipeline: Five digital-first launches this quarter on Zanducare, with management very bullish on scaling them in the current and coming quarters.
Mohan Goenka: "now that the margins are pretty high in toothpaste, particularly this Ayurvedic segment, we strongly believe that Zandu has right to win because Zandu, in Ayurveda is a very well established brand and we were working on the formulation for quite some time, I think we have a winner formulation."
Margins & Input Costs
- Gross margin expanded 290 bps to 68.8%: Favorable input costs were the primary driver, with menthol, LLP and other key raw materials remaining benign and no pressure visible on the horizon.
- D2C margin trajectory improving: Man Company shifted from negative to positive EBITDA on operating leverage from ~80% growth; Brillare’s negative EBITDA margin halved from 40-45% to minus 20% as scale built.
- Modern trade and e-commerce: Management sees further room to expand margins in both channels, though no specific timeline was given.
- Pricing outlook: The company typically aims for roughly 3% annual price increases and expects to stick to that number next year.
Gul Raj Bhatia: "It would not be at a premium like we would have other products in the category because there is a certain price point in the category, but definitely in terms of the formulation, we got certain ingredients which are much more efficacious."
D2C & Channel Strategy
- Zanducare scaling: The platform has reached a critical mass to scale going forward, with month-on-month and quarter-on-quarter growth already visible.
- Dantveer distribution path: Management plans to take the toothpaste to retail and larger markets, leveraging the high margins now available in the Ayurvedic toothpaste segment.
- D2C poised vs peers: Digital-first products in the D2C segment are doing relatively much better than both larger and smaller players who entered the market in the last 2-3 years.
- Emerging channels: Accelerated scale-up of emerging channels, distribution initiatives, and D2C portals are identified as key growth drivers alongside strategic investments and the innovation pipeline.
Mohan Goenka: "Man Company, there is a big shift which was a negative EBITDA margin has become positive because our growth has been almost 80%. So, due to the scale up, the brand is now making profits. Same is with Brillare, the negative EBITDA margins which was in the tune of almost 40%-45% has come down to minus 20%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth target | 6% to 8% volume growth | No specific quarter; market conditions cited as a caveat |
| Price increase | Roughly 3% price increase | Next year (FY25) |
| Healthcare growth | Strong double-digit growth | Current and going-forward quarters/years |
| Pledge reduction | Bring pledge down to single digits from current 12% | No specific quarter given |
| Effective tax rate | Around 10% considering MAT credit entitlements | Q4 FY24 and next year |
| Kesh King recovery | Bounce back to at least 6% to 8% growth once market revives | Conditional on market revival; possibly Q4 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹996 cr, +1.4% YoY; volume declined 0.9% |
| Domestic non-winter portfolio growth | +5% |
| Gross margin | 68.8%, expanded 290 bps YoY |
| EBITDA | ₹315 cr, +7% YoY; margin 31.6%, up 170 bps |
| PAT | ₹258 cr, +9% YoY; margin 25.9%, up 180 bps |
| 9M FY24 revenue growth | ~5% YoY |
| 9M FY24 EBITDA margin | 27.5%, up 170 bps YoY |
| 9M FY24 PAT | ₹575 cr, +16% YoY |
| International business growth | +8% in INR terms, +11% in constant currency |
| Navratna and Dermicool range growth | +7% |
| Pain management portfolio growth | +3%; represents 26% of revenues |
| Healthcare range (ex-Chyawanprash and honey) growth | +3%; overall healthcare flat |
| BoroPlus growth | -9%, due to late onset and mild winter |
| Male Grooming range growth | -6% |
| Kesh King range growth | -13%; 4-year CAGR +5% vs pre-COVID |
| Helios and Brillare Science growth | +80% |
| Modern trade and e-commerce saliency | 22% of sales; modern trade +10%, e-commerce +17% |
| 7 Oils in One growth | -5% in Q3; flat for 9M FY24 |
| Winter portfolio decline | ~9% |
| Man Company profitability | EBITDA positive, from negative; growth ~80% |
| Brillare EBITDA margin | -20%, improved from -40% to -45% |
| Promoter pledge | 12% |
| Effective tax rate (9M FY24) | 7.7%; expected ~10% for Q4 and next year |
| Net cash | ~₹400 cr |
| Second interim dividend | ₹4 per share (400%) |